Clinical Trials Logo

NSCLC Stage IV clinical trials

View clinical trials related to NSCLC Stage IV.

Filter by:

NCT ID: NCT03341494 Recruiting - Chemotherapy Effect Clinical Trials

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Start date: April 1, 2017
Phase: Phase 2
Study type: Interventional

EGFR-TKIs are the standard first-line treatment option for EGFR-mutant NSCLC. After a randomized phase II trial, JO25567 was presented at 2014 ASCO, the synergistic effect of progression-free survival(PFS) could be expected when EGFR TKI, Gefitinib is combined with Antiangiogenesis agent thalidomide, Therefore Chinese data of treating EGFR mutation positive NSCLC patients with Gefitinib and thalidomide is significantly necessary for developing new standard treatment in first-line therapy in Chinese EGFR mutant NSCLC patients. In this study, The investigators will investigate the efficacy and safety of Gefitinib and thalidomide combination compare to Gefitinib alone in Chinese EGFR-mutant NSCLC patients.